Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,406 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Benefit Clear all
Completed Phase 1 Interventional Results available

HDCRT Plus Pembrolizumab in Advanced Malignancies

NCT02987166
View directory record Official record
Conditions
Solid Tumor
Interventions
High-Dose Conformal Radiation Therapy, Pembrolizumab
Radiation · Drug
Lead sponsor
James Larner, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

NCT02924402
View directory record Official record
Conditions
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
XmAb13676
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Physical Activity as Self-Management Approach to Improve Health Outcomes in AML

NCT02584296
View directory record Official record
Conditions
Leukemia, Myeloid, Monocytic
Interventions
BSMA
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 25, 2026, 6:33 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT03547973
View directory record Official record
Conditions
Metastatic Urothelial Cancer
Interventions
Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
30
States / cities
Tucson, Arizona • San Francisco, California • Littleton, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fruit And Vegetable Or Recreation Prescriptions for UW-Madison Students

NCT02870322
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Fruit and Vegetable CSA Prescription, Bikeshare Prescription
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 24 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors

NCT00355888
View directory record Official record
Conditions
Cancer
Interventions
MBP-426
Drug
Lead sponsor
Mebiopharm Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Cash Transfers to Address Child Welfare Involvement

NCT05857553
View directory record Official record
Conditions
Child Poverty
Interventions
Unconditional Cash Transfer, No Direct Cash Transfer
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

NCT01436227
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Laboratory Biomarker Analysis, Pazopanib Hydrochloride
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03739372
View directory record Official record
Conditions
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions
Specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 6:33 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

NCT02158936
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
Eltrombopag, Azacitidine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Combined School- and Home-Based Sleep Promotion Program

NCT06131944
View directory record Official record
Conditions
Sleep
Interventions
Rested & Ready to Learn
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
4 Years to 6 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 25, 2026, 6:33 AM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Improve Caregiver Palliative Care Knowledge and Attitudes

NCT05162807
View directory record Official record
Conditions
Cancer
Interventions
Psychoeducational Video on Palliative Care, Educational Video on Nutrition
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Stress Management Therapy in Patients Receiving Chemotherapy for Cancer

NCT00377130
View directory record Official record
Conditions
Cancer, Psychological Stress, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Self Administered Stress Management
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
46
States / cities
Martinez, California • Oakland, California • Washington D.C., District of Columbia + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 25, 2026, 6:33 AM EDT
Active, not recruiting Phase 4 Interventional

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics Switzerland GmbH
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
34
States / cities
Burbank, California • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Longitudinal, Multi-Dimensional Assessment of Recovery and Added Benefit of a Behavioral Health Intervention for Children With Abusive Head Trauma

NCT03447899
View directory record Official record
Conditions
Non-Accidental Traumatic Head Injury to Child
Interventions
Attachment and Biobehavioral Catch-up (ABC)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Months to 2 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System

NCT00205881
View directory record Official record
Conditions
Hearing Loss
Interventions
HiRes 90K Bionic Ear System
Device
Lead sponsor
Advanced Bionics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 25, 2026, 6:33 AM EDT
Recruiting Not applicable Interventional

Mindfulness in Chronic Kidney Disease

NCT04099992
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Mindfulness-based stress reduction (MBSR), Health enhancement program (HEP), Transcutaneous Vagus Nerve Stimulation (tVNS), Sham-transcutaneous Vagus Nerve Stimulation (tVNS)
Behavioral · Device
Lead sponsor
Emory University
Other
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

NCT02766699
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
EGFR(V)-EDV-Dox
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 25, 2026, 6:33 AM EDT
Completed No phase listed Observational Results available

Email Campaign to Increase Uptake of myGeisinger

NCT04332614
View directory record Official record
Conditions
Telehealth, Health Behavior
Interventions
Less-is-better, Social proof, Endowment / decision staging, Standard email
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 88 Years
Enrollment
14,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 25, 2026, 6:33 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland

NCT06426004
View directory record Official record
Conditions
Normal Pressure Hydrocephalus, Hakim Syndrome
Interventions
patients will receive NPH education, primary care physicians (PCPs) will receive professional NPH education, A community health worker will assist PCP
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
65 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2032
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

NCT01180049
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
temsirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Miami, Florida • East Orange, New Jersey • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 25, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Text Message Quit Vaping Intervention for Adolescents

NCT04919590
View directory record Official record
Conditions
Vaping, Cessation, Tobacco
Interventions
This is Quitting, Assessment only control, Waitlist control
Behavioral · Other
Lead sponsor
Truth Initiative
Other
Eligibility
13 Years to 17 Years
Enrollment
1,681 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 25, 2026, 6:33 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

NCT03059940
View directory record Official record
Conditions
Smoking Cessation
Interventions
Questionnaires, Low Dose Computed Tomography Scan, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, Carbon Monoxide (CO) Level Test
Behavioral · Procedure · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years and older
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 6:33 AM EDT